Squamous cells detection

Y.C. Yoon, K.S. Lee, Y.M. Shim, B.T. Kim, K. Kim, T.S. Kim, Metastasis to regional lymph nodes In patients with esophageal squamous cell carcinoma CT versus FDG PET for presurgical detection prospective study. Radiology 227(3) (2003) 764-770. 

NT071 Lazarus, P., A. M. Idris, J. Kim, A. Calcagnotto, and D. Hoffmann. p53 mutations in head and neck squamous cell carcinomas from Sudanese snuff (toombak) users. Cancer Detect Prev 1996 20(4) 270-278. 

Piffko, J., Bankfalvi, A., Ofner, D., Joos, U., Bocker, W., and Schmid, K. W. 1995. Immunohistochemical detection ofp53 protein in archival tissues from squamous cell carcinomas of the oral cavity using wet autoclave antigen retrieval. J. Pathol. 776 69-75. 

The combination of top-down and bottom-up strategies on the salivary characterization presents the advantages of each one and relied on the identification of more than 2000 different peptides (5,27,35-37,40—42). From those, only about 30-40% identified peptides belong to the major salivary peptide classes referred in the preceding text, the remnant peptides originating from sources such as plasma, squamous cells, and crevicular fluid. Peptides of major classes are usually detected by LC-MS analysis, independently of intra- and interindividual variability. Indeed, a repertoire of 233 masses belonging to these naturally occurring peptides has been consistently detected by LC-ESI-MS analysis of the salivary peptidome (43). 

In 1968, Fishman and his collaborators reported the identification of an ALP in the serum of a patient with metastatic squamous cell carcinoma of the lung that was biochemicaEy and immunologicaUy identical with the ALP of a normal placenta. The newly discovered isoenzyme was termed the Regan isoenzyme after the patient in whom it was discovered. The Regan isoenzyme has been detected in tumor tissues and in sera of patients with many types of malignant disease and in some patients with nonmalignant diseases. An incidence of the isoenzyme of 3% to 15% in sera of cancer patients has been estimated, but this varies with the sensitivity of the methods used for its detection. Other variant forms of ALP have since been discovered in tumor tissues. These variants show many similarities to normal placental ALP but may differ in other properties, such as response to certain inhibitors. 

CRA has been detected in humans [34] and was the first RAR-RXR pan-agonist discovered [35-37] and may be classified as a retinoid/rexinoid. It is the only retinoic acid isomer not approved for the common dermatological diseases. However, it has recently been launched in the US as adjuvant topical treatment of AIDS-associated Kaposi s sarcoma [38-41]. This agent is the first RXR ligand to be approved for the treatment of a dermatological disease. In a randomized study with 268 AIDS-associated Kaposi s sarcoma patients, 35% treated with alitretinoin (0.1% gel) had a positive response, compared with 18% treated with vehicle gel irrespective of the number of concurrent antiretroviral therapies [41], 9-CRA is in clinical trials for the treatment of various cancers, including breast cancer [42], renal cell carcinoma [43,44] and squamous cell carcinoma [45—47]. 

---